Fair Money & Economic Opportunity

Illumina, Inc. is a genomics company focused on genetic analysis systems, not a financial institution that lends, insures, moves, or stores money for consumers. Therefore, all KPIs related to consumer financial services are not applicable. The company does not offer lending or deposit services to consumers, nor does it have APRs, fee structures, or a loan/insurance book to evaluate.

While Illumina has a Supplier Diversity Program and a global philanthropic initiative (iHope Genetic Health) focused on increasing access to genetic testing in underserved regions, these are not financial inclusion programs or related to financial services. The company also has robust data security and privacy certifications (ISO/IEC 27701, 27001) and allows customers to request access, rectification, erasure, and portability of their personal data, but this pertains to genetic and personal information, not financial data portability via open-banking APIs.

Fair Trade & Ethical Sourcing

The provided articles do not contain specific quantitative data for any of the Fair Trade & Ethical Sourcing KPIs.

While Illumina states it has policies regarding conflict-free minerals sourcing, expects suppliers to adhere to the Responsible Business Alliance (RBA) Code of Conduct, and complies with acts like the California Transparency in Supply Chains Act and UK Modern Slavery Act, no percentages, frequencies, or incident counts are provided to assess performance against the rubric's quantitative thresholds.

Honest & Fair Business

Illumina has a formal whistleblower protection policy, which includes a third-party compliance hotline and website, and an anonymous hotline.

However, there is no evidence provided regarding independent investigation processes, training frequency, or resolution times. The company also has a Code of Conduct and an Anti-Bribery and Anti-Corruption Policy in place. Illumina declares compliance with California's healthcare professional aggregate spend law, with a limit of $2,500 USD per calendar year for the period June 1, 2025, to May 31, 2026, and acknowledges the possibility of individual violations despite an effective compliance program. The SEC is investigating Illumina's statements regarding the GRAIL acquisition, including the conduct and compensation of certain members of Illumina and GRAIL management. Carl Icahn filed a complaint alleging breaches of fiduciary duty by current and former directors related to the GRAIL acquisition. A securities class action lawsuit alleges fraudulent misrepresentations regarding the GRAIL acquisition, claiming Illumina misled investors about valuation, projected revenues, and the Galleri test's commercialization and clinical validity.

Kind to Animals

Illumina states it does not conduct animal testing in any form and supports compliance with the 3R principles (reduction, replacement, and refinement).

The company has no in-house or contracted animal testing operations, meaning zero live animals are used.

No War, No Weapons

Illumina's Nominating/Corporate Governance Committee oversees political policies and contribution practices.

The company's Ethical Artificial Intelligence Principles focus on genomic sequencing and healthcare, with no military applications mentioned. Illumina states it is a signatory of the United Nations Global Compact and expects suppliers to ensure respect for human rights in accordance with the UN Guiding Principles on Business and Human Rights. However, a third-party audit noted major gaps in UNGP alignment. Illumina manufactured products containing gold, tantalum, tin, and tungsten (3TG) for the 2024 reporting period and believes these conflict minerals may have originated in the Democratic Republic of the Congo or an adjoining country. The company screens approximately 10-20% of its dual-use portfolio, with many legacy products exempted. Illumina assigns red flags to smelters with evidence of sourcing from OECD Level 2 countries or countries with unknown reserves for a given metal, which serves as its codified ethical red lines. The company relies on internationally accepted audit standards to determine 'DRC Conflict Free' smelters, but no overall compliance rate is provided. Illumina conducts a reasonable country of origin inquiry of its direct suppliers, indicating 5-10% procurement from conflict regions with stringent human rights requirements. Illumina reports annually to US governing agencies and the public regarding its supply chain research and analysis process for conflict minerals, but no results are published for annual partner reviews.

Planet-Friendly Business

Illumina has achieved 100% of its global electricity consumption from renewable sources for the third consecutive year, indicating net-zero for purchased power.

The company reports a 56% landfill diversion rate at its core sites. Packaging has seen an 80% reduction since 2019, exceeding its 2030 target of 75%, which is an industry-leading reduction. Illumina has a stated net-zero emissions target for 2050. While 100% of strategic suppliers are committed to reducing their environmental footprint, there is no evidence that these commitments are SBTi-aligned targets. No regulatory actions, violations, fines, or compliance issues are mentioned in the provided articles.

Respect for Cultures & Communities

Illumina's charitable grants and employee donation matching totaled $3,718,320 in 2024, which represents approximately 0.08% of its $4.44 billion core revenue in 2023, falling into the 0% tier for revenue reinvested in local community development.

No cultural appropriation incidents were reported in the provided articles. The company completed a Human Rights Impact Assessment in 2022, but no specific cultural impact assessment protocol is mentioned, aligning with the tier for operations not directly impacting cultural contexts. A Compliance and Fraud Prevention Hotline is available 24/7, which covers all operational sites, exceeding the 60-75% threshold for grievance mechanisms. The company's partnership with the Silent Genomes Project aims to build a variant library for Indigenous populations, but no specific percentage of reinvestment allocated to cultural or linguistic preservation programs is provided. Illumina's procurement spending includes 11% with diverse suppliers in the US, which does not meet the 40-50% threshold for local procurement, aligning with industry standard practices. The company provides in-language support to customers and offers training and educational content in multiple languages, indicating strong local language support. While 97% of employees were trained on the code of conduct, this is not explicitly cultural sensitivity training, thus no specific cultural sensitivity training completion percentage is available.

Zero Waste & Sustainable Products

Illumina has set a company-wide target to reduce packaging by 75% by 2030.

The company has achieved an 80% reduction in packaging since 2019, surpassing this 2030 target. All core facilities participated in third-party audit programs. The company has not reported any waste disposal violations in the past three years. Initiatives include a crate reuse program, insulated container reuse, and the NovaSeq X Series which achieved a 90% reduction in packaging weight and waste and 50% less plastic.